Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients

Journal of the American Academy of Dermatology

Volumn 65, Issue 3, 2011, Pages 546-551

  Kothary, Namita ^a   Diak, Ida Lina ^a   Brinker, Allen ^a   Bezabeh, Shewit ^a   Avigan, Mark ^a   Dal Pan, Gerald ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

biologics; demyelinating disorders; efalizumab; pharmacoepidemiology; progressive multifocal leukoencephalopathy; psoriasis

Indexed keywords

ADALIMUMAB; ALEFACEPT; ANTITHROMBOCYTIC AGENT; ANTIVIRUS AGENT; CALCIPOTRIOL; EFALIZUMAB; ETANERCEPT; HYDROCORTISONE; IMMUNOGLOBULIN; INFLIXIMAB; MEFLOQUINE; METHOTREXATE; TRIAMCINOLONE; VIRUS DNA;

ADULT; AGED; ARM WEAKNESS; ARTICLE; BEHAVIOR CHANGE; CASE REPORT; CAUSE OF DEATH; DATA BASE; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG WITHDRAWAL; EYE MOVEMENT DISORDER; FACIAL NERVE PARALYSIS; FATIGUE; FEMALE; FOOD AND DRUG ADMINISTRATION; GAIT DISORDER; HUMAN; JC VIRUS; LONG TERM CARE; MALE; MENTAL HEALTH; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESTHESIA; PLASMAPHERESIS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; RISK FACTOR; SIDE EFFECT; SKIN SENSATION; SPEECH DISORDER; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT RESPONSE; VERTIGO;

AGED; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MALE; MIDDLE AGED; PSORIASIS;

EID: 80051791145     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2010.05.033     Document Type: Article

References (31)

1. T. Weber Progressive multifocal leukoencephalopathy Neurol Clin 26 2008 833 854 (Pubitemid 352020489)
2. E.O. Major, K. Amemiya, C.S. Tornatore, S.A. Houff, and J.R. Berger Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain Clin Microbiol Rev 5 1992 49 73
3. W. Wenning, A. Haghikia, J. Laubenberger, D.B. Clifford, P.F. Behrens, and A. Chan Treatment of progressive multifocal leukoencephalopathy associated with natalizumab N Engl J Med 361 2009 1075 1080
4. H. Linda, A. von Heijne, E.O. Major, C. Ryschkewitsch, J. Berg, and T. Olsson Progressive multifocal leukoencephalopathy after natalizumab monotherapy N Engl J Med 361 2009 1081 1087
5. B.F. Sabath, and E.O. Major Traffic of JC virus from sites of initial infection to the brain: The path to progressive multifocal leukoencephalopathy J Infect Dis 186 Suppl 2 2002 S180 S186
6. P.M. Eng, B.R. Turnbull, S.F. Cook, J.E. Davidson, T. Kurth, and J.D. Seeger Characteristics and antecedents of progressive multifocal leukoencephalopathy in an insured population Neurol 67 2006 884 886 (Pubitemid 44394211)
7. Campath (alemtuzumab) Prescribing Information March 2009 Bayer HealthCare Pharmaceuticals, Inc Wayne (NJ)
8. Arranon (nelarabine) Prescribing Information July 2006 GlaxoSmithKline Research Triangle Park (NC)
9. Fortovase (saquinavir) Prescribing Information December 2003 Roche Laboratories, Inc Nutley (NJ)
10. Invirase (saquinavir mesylate) Prescribing Information July 2007 Roche Laboratories, Inc Nutley (NJ)
11. Y. Chen, E. Bord, T. Tompkins, J. Miller, C.S. Tan, and R.P. Kinkel Asymptomatic reactivation of JC virus in patients treated with natalizumab N Engl J Med 361 2009 1067 1074
12. E.S. Molloy, and L.H. Calabrese Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases Arthritis Rheum 60 2009 3761 3765
13. Raptiva (efalizumab) Prescribing Information March 2009 Genentech, Inc South San Francisco (CA)
14. Food and Drug Administration. FDA Approval Letter for BLA 125075 (efalizumab, Raptiva) dated October 27, 2003. Available at: http://www. accessdata.fda.gov/drugsatfda-docs/appletter/2003/125075-0ltr.pdf. Accessed Sept 11, 2009.
15. Raptiva (efalizumab) Prescribing Information October 2008 Genentech, Inc South San Francisco (CA)
16. Food and Drug Administration. FDA statement on the voluntary withdrawal of Raptiva from the U.S. market. Available at: http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm149561.htm. Accessed June 23, 2009.
17. A. Menter, A. Gottlieb, S.R. Feldman, A.S. Van Voorhees, C.L. Leonardi, and K.B. Gordon Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics J Am Acad Dermatol 58 2008 826 850 (Pubitemid 351509656)
18. S.R. Feldman, J.Y.M. Koo, A. Menter, and J. Bagel Decision points for the initiation of systemic treatment for psoriasis J Am Acad Dermatol 53 2005 101 107 (Pubitemid 40826702)
19. Humira (adalimumab) Prescribing Information March 2009 Abbott Laboratories North Chicago (IL)
20. Amevive (alefacept) Prescribing Information March 2009 Astellas Pharma US, Inc Deerfield (IL)
21. Enbrel (etanercept) Prescribing Information April 2009 Amgen Inc and Wyeth Pharmaceuticals Thousand Oaks (CA)
22. Remicade (infliximab) Prescribing Information April 2009 Centocor Ortho Biotech, Inc Malvern (PA)
23. Stelara (ustekinumab) Prescribing Information September 2009 Centocor Ortho Biotech, Inc Horsham (PA)
24. Food and Drug Administration. Adverse event reporting system (AERS). Available at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/ Surveillance/AdverseDrugEffects/default.htm. Accessed June 23, 2009.
25. Code of Federal Regulations, Title 21, Volume 5, revised April 1, 2009. 21 CFR 314.80: Postmarketing reporting of adverse drug experiences. Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr= 314.80. Accessed Oct 14, 2009.
26. MedDra MSSO and Northrop Grumman. MedDRA. Available at: http://www.meddramsso.com. Accessed Oct 14, 2009.
27. P. Cinque, I.J. Koralnik, and D.B. Clifford The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: defining a consensus terminology J Neurovirol 9 Suppl 1 2003 88 92 (Pubitemid 36656477)
28. P. Tubert, B. Bégaud, J.C. Péré, F. Haramburu, and J. Lellouch Power and weakness of spontaneous reporting: a probabilistic approach J Clin Epidemiol 45 1992 283 286
29. Centers for Disease Control and Prevention. Laboratory Procedure Manual: CD4+ T-lymphocytes and CD8 T cells. Available at: http://www.cdc.gov/Nchs/data/ nhanes/nhanes-03-04/l03-c-met-CD4%2B-CD8%2B.pdf. Accessed Oct 27, 2009.
30. Genentech, Inc. Genentech statement to Healthcare Professionals: Important safety information. Available at: http://www.gene.com/gene/products/ information/pdf/raptiva-dhcp.pdf. Accessed June 20, 2009.
31. S. Gheuens, G. Pierone, P. Peeters, and I.J. Koralnik Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression J Neurol Neurosurg Psychiatry 81 2010 247 254